Answers are grounded in this paper and cite their sources.
// Mirko Dengler 1, * , Katharina Staufer 2, 12, * , Heidemarie Huber 1 , Rudolf Stauber 3 , Heike Bantel 4 , Karl Heinz Weiss 5 , Patrick Starlinger 6 , Hannelore Pock 3 , Petra Klöters-Plachky 5 , Daniel N. Gotthardt 5 , Peter Rauch 7 , Carolin Lackner 8 , Judith Stift 9 , Christine Brostjan 6 , Thomas Gruenberger 6 , Takashi Kumada 10 , Hidenori Toyoda 10 , Toshifumi Tada 10 , Thomas S. Weiss 11 , Michael Trauner 12 and Wolfgang Mikulits 1 1 Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria 2 Department of Surgery, Division of Transplantation, Medical University of Vienna, Vienna, Austria 3 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria 4 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany 5 University Hospital Heidelberg, Heidelberg, Germany 6 Department of Surgery, Division of General Surgery, Medical University of Vienna, Vienna, Austria 7 Candor Bioscience GmbH, Wangen im Allgäu, Germany 8 Institute of Pathology, Medical University of Graz, Graz, Austria 9 Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria 10 Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan 11 Center for Liver Cell Research, Children’s University Hospital (KUNO), University of Regensburg Hospital, Regensburg, Germany 12 Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria * These authors have contributed equally to this work Correspondence to: Wolfgang Mikulits, email: wolfgang.mikulits@meduniwien.ac.at Keywords: soluble Axl, biomarker, fibrosis, cirrhosis, hepatocellular carcinoma Received: September 01, 2016 Accepted: April 06, 2017 Published: May 03, 2017 ABSTRACT Patients with chronic liver disease (CLD) and cirrhosis are at high risk for hepatocellular carcinoma (HCC). Current diagnostic tools for HCC detection include imaging techniques and serum biomarkers such as α-fetoprotein (AFP). Yet, these methods are limited in sensitivity and specificity to accurately detect early HCC. Here we focused on the potential of soluble Axl (sAxl) as a biomarker in CLD patients by analyzing serum samples of 1067 patients and healthy controls from centers in Europe and Asia. We show that serum concentrations of sAxl were significantly increased at early (82.57 ng/mL) and later stages of HCC (114.50 ng/mL) as compared to healthy controls (40.15 ng/mL). Notably, no elevated sAxl levels were detected in patients with CLD including chronic viral hepatitis, autoimmune hepatitis, cholestatic liver disease, or non-alcoholic fatty liver disease versus healthy controls. Furthermore, sAxl did not rise in liver adenomas or cholangiocarcinoma (CCA). Yet, patients with advanced fibrosis (F3) or cirrhosis (F4) showed enhanced sAxl concentrations (F3: 54.67 ng/mL; F4: 94.74 ng/mL). Hepatic myofibroblasts exhibited an increased release of sAxl, suggesting that elevated sAxl levels arise from these cells during fibrosis. Receiver operating characteristic curve analysis of sAxl displayed a strongly increased sensitivity and specificity to detect both cirrhosis (80.8%/92.0%) and HCC (83.3%/86.7%) with an area under the curve of 0.935/0.903 as compared to AFP. In conclusion, sAxl shows high diagnostic accuracy at early stage HCC as well as cirrhosis, thereby outperforming AFP. Importantly, sAxl remains normal in most common CLDs, liver adenomas and CCA.
No takes yet. Share an insight, caveat, or question.
Dengler et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: